Skip to main content
Top
Published in: International Journal of Clinical Oncology 5/2014

01-10-2014 | Original Article

Questionnaire survey for the development and publication of cancer clinical practice guidelines in Japan

Authors: Tomohisa Furuhata, Koichi Hirata, Fumihiko Wakao, Kenji Okita, Masafumi Imamura, Yoshihiko Maehara, Masahiko Nishiyama

Published in: International Journal of Clinical Oncology | Issue 5/2014

Login to get access

Abstract

Purpose

To understand the current situation of the development and publication of cancer clinical practice guidelines and discuss an ideal structure in future.

Methods

A questionnaire survey pertaining to the development and publication of cancer clinical practice guidelines was conducted with funding by a Health and Labour Sciences Research Grant. Respondents included presidents and chairpersons of academic societies developing guidelines and members of the Cancer Guidelines Committee of the Japan Society of Clinical Oncology who were specialists in various cancer sites.

Results

Concerning the question of funding for the development and publication of the guidelines, 80.7 % of respondents indicated that partial public funding is required. As for the flow of public funds, 80.4 % of respondents thought that funds should be distributed appropriately to each academic society by a third-party organization. Regarding the question about the publication of the guidelines, 82.5 % of respondents replied that a comprehensive publication site needs to be established. In terms of the choice of organization that would be responsible for setting up and managing this site, the responses varied as follows: “a newly established organization” (38.3 %); “Center for Cancer Control and Information Services” (29.8 %); “Japan Society of Clinical Oncology” (23.4 %); and “Medical Information Network Distribution Service” (23.4 %) (multiple answers allowed).

Conclusion

While the guidelines should be developed voluntarily by each academic society, partial public funding is also considered to be necessary for maintaining the continuous revision process. As for the publication of the guidelines, the establishment of a new comprehensive publication site would improve user convenience.
Literature
1.
go back to reference Winn RJ (2000) The NCCN guidelines development process and infrastructure. Oncology 14(11A):26–30PubMed Winn RJ (2000) The NCCN guidelines development process and infrastructure. Oncology 14(11A):26–30PubMed
2.
go back to reference Taylor R (2001) Using health outcomes data to inform decision-making: government agency perspective. Pharmacoeconomics 19(Suppl 2):33–38PubMedCrossRef Taylor R (2001) Using health outcomes data to inform decision-making: government agency perspective. Pharmacoeconomics 19(Suppl 2):33–38PubMedCrossRef
3.
go back to reference Shimbo T, Fukui T, Ishioka C et al (2010) Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology. Int J Clin Oncol 15(3):227–233PubMedCrossRef Shimbo T, Fukui T, Ishioka C et al (2010) Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology. Int J Clin Oncol 15(3):227–233PubMedCrossRef
Metadata
Title
Questionnaire survey for the development and publication of cancer clinical practice guidelines in Japan
Authors
Tomohisa Furuhata
Koichi Hirata
Fumihiko Wakao
Kenji Okita
Masafumi Imamura
Yoshihiko Maehara
Masahiko Nishiyama
Publication date
01-10-2014
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 5/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-014-0715-1

Other articles of this Issue 5/2014

International Journal of Clinical Oncology 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine